NovaBay, a bio-pharmaceutical company focused on products to prevent a wide range of infections, priced its 5 million share offering at $4, the low end of the expected range. The stock is expected to begin trading on the AMEX on Friday, under the ticker "NBY". Dundee and Desjardins Securities were the lead managers on the deal.
